Clinical trials: Graves Orbitopathy
Graves' Disease
Role of the Microbiome in Graves' Orbitopathy
Graves' orbitopathy (GO), also known as thyroid eye disease, affects approximately 3 million people in Europe with an estimated socioeconomic burden of 6.4 billion euros per annum.
- Trial name
- Indigo (NCT02373995)
- Testing
- LAB4
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves Orbitopathy
Immunological Follow-up of Patients With Basedow's Orbitopathy
Graves' disease is characterized by the combination of anti-TSH receptor antibodies (Thyroid-Stimulating Hormone or thyroidotropic hormone), specific to this disease, with inconsistent symptoms such as hyperthyroidism…
- Trial name
- SIPO (NCT04610723)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with…
- Trial name
- UplighTED (NCT06307613)
- Testing
- Efgartigimod PH20 SC
- Where
- 77 sites in United States, Australia and 14 more
- Volunteers
- 102 people
- Sponsor
- argenx
Graves' Ophthalmopathy
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
- Trial name
- NCT01969019
- Testing
- methylprednisolone, prednisone
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ruijin Hospital
Thyroid Eye Disease
Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy
Graves' orbitopathy (GO) is an disfiguring and disabling autoimmune condition. Sight-threatening GO is an most severe form and occurs in about 5% of patients with Graves' disease.
- Trial name
- NCT05627401
- Testing
- Modified multiple orbital wall decompression
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Optic Neuropathy
- Trial name
- NCT07594912
- Testing
- Teprotumumab N01, Intravenous Methylprednisolone (IVMP)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Bioavailability, Bioequivalence
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
- Trial name
- NCT06563856
- Testing
- TEPEZZA, EDP
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Amgen
Graves Ophthalmopathy
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
The purpose of this study is to examine the effects of Azithromycin (a macrolide class antibiotic), given three times weekly, for patients with active moderate-severe, non sight-threatening, Graves Orbitopathy.
- Trial name
- NCT01379196
- Testing
- Azithromycin
- Sponsor
- Rabin Medical Center
Thyroid Eye Disease, Graves Orbitopathy
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- LIDS (NCT05276063)
- Testing
- Linsitinib
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 90 people
- Sponsor
- Sling Therapeutics, Inc.
Dysthyroid Ophthalmopathies
mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX)
The dysthyroid orbitopathy (DO) is a chronic disease, evolving during 2 to 3 years, with a hypertrophy and a variable degree of inflammation of the eyelid muscles, the oculomotor muscles and the orbital fat.
- Trial name
- DDX (NCT02397109)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Thyroid Disease
Local Triamcinolone Injection in Active Thyroid Orbitopathy
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.
- Trial name
- NCT01280214
- Testing
- Triamcinolone
- Volunteers
- 30 people
- Sponsor
- HaEmek Medical Center, Israel
Thyroid Eye Disease, TED
Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the…
- Trial name
- NCT07056114
- Testing
- The patients with active or inactive TED
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Keratoconus, Corneal Ectasia
Corneal Tomographic Parameters in TGD
The current study involved analysis of the corneal tomographic parameters of patients with thyroid gland dysfunction (hyperthyroidism or hypothyroidism), including those with an autoimmune etiology, in comparison to healthy…
- Conditions
- Keratoconus, Corneal Ectasia, Thyroid Eye Disease
- Trial name
- NCT04433936
- Testing
- Pentacam tomography
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ameera Gamal Abdelhameed
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease
ASTED (Antioxidant Supplements for TED) trial is an investigator-initiated, randomized, triple masked, clinical trial of a selected combination of vitamins and minerals versus placebo in patients with moderate to severe thyroid…
- Trial name
- NCT02422368
- Testing
- Methylprednisolone + ASTED
- Where
- 2 sites in Iran
- Sponsor
- Iran University of Medical Sciences
Thyroid Associated Ophthalmopathy
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied.
- Trial name
- NCT03107078
- Testing
- Glucocorticoids
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jie Shen
Graves' Ophthalmopathy
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with…
- Trial name
- NCT00430547
- Testing
- Carbimazole, radio-active iodine (I131)
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Barwon Health
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Dysthyroid Orbitopathy
Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy
The purpose of this protocol is to study orbital structures in Graves´ Disease using multidetector computed tomography and color doppler imaging.
- Trial name
- NCT00665795
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo